Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis
Laura Turco, Cándid Villanueva, Vincenzo La Mura, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 2, pp. 313-327.e6
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Guidelines on the management of ascites in cirrhosis
Guruprasad P. Aithal, Naaventhan Palaniyappan, Louise China, et al.
Gut (2020) Vol. 70, Iss. 1, pp. 9-29
Open Access | Times Cited: 549
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
Naga Chalasani, Manal F. Abdelmalek, Guadalupe García‐Tsao, et al.
Gastroenterology (2019) Vol. 158, Iss. 5, pp. 1334-1345.e5
Open Access | Times Cited: 266
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 265
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
David E. Kaplan, Cristina Ripoll, Maja Thiele, et al.
Hepatology (2023) Vol. 79, Iss. 5, pp. 1180-1211
Open Access | Times Cited: 132
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 50
Beta-blockers in cirrhosis: Evidence-based indications and limitations
Susana Rodrigues, Yuly P. Mendoza, Jaime Bosch
JHEP Reports (2019) Vol. 2, Iss. 1, pp. 100063-100063
Open Access | Times Cited: 135
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
Guadalupe García‐Tsao, Jaime Bosch, Zeid Kayali, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 5, pp. 885-895
Open Access | Times Cited: 134
Where does TIPS fit in the management of patients with cirrhosis?
Juan Carlos García‐Pagán, Saad Saffo, Mattias Mandorfer, et al.
JHEP Reports (2020) Vol. 2, Iss. 4, pp. 100122-100122
Open Access | Times Cited: 106
Portal Hypertension
Laura Turco, Guadalupe García‐Tsao
Clinics in Liver Disease (2019) Vol. 23, Iss. 4, pp. 573-587
Closed Access | Times Cited: 98
The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis
Thomas Reiberger
Hepatology Communications (2021) Vol. 6, Iss. 5, pp. 950-964
Open Access | Times Cited: 90
Evaluation and Management of Esophageal and Gastric Varices in Patients with Cirrhosis
Simona Jakab, Guadalupe García‐Tsao
Clinics in Liver Disease (2020) Vol. 24, Iss. 3, pp. 335-350
Open Access | Times Cited: 70
New clinical and pathophysiological perspectives defining the trajectory of cirrhosis
Rajiv Jalan, Gennaro D’Amico, Jonel Trebicka, et al.
Journal of Hepatology (2021) Vol. 75, pp. S14-S26
Open Access | Times Cited: 70
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension
Laura Turco, Thomas Reiberger, Giovanni Vitale, et al.
Liver International (2023) Vol. 43, Iss. 6, pp. 1183-1194
Open Access | Times Cited: 38
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Wiener klinische Wochenschrift (2023) Vol. 135, Iss. S3, pp. 493-523
Open Access | Times Cited: 23
Pathophysiology and therapeutic options for cirrhotic portal hypertension
Sergi Guixé‐Muntet, Sergio Quesada‐Vázquez, Jordi Gracia‐Sancho
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 646-663
Closed Access | Times Cited: 10
Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the ‘CAVARLY TRIAL’
Harsh Vardhan Tevethia, Apurva Pande, Rajan Vijayaraghavan, et al.
Gut (2024) Vol. 73, Iss. 11, pp. 1844-1853
Closed Access | Times Cited: 10
A machine learning based algorithm accurately stages liver disease by quantification of arteries
Zhengxin Li, Xin Sun, Zhimin Zhao, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Preventing the progression of cirrhosis to decompensation and death
Cándid Villanueva, Dhiraj Tripathi, Jaime Bosch
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 1
Precision medicine in variceal bleeding: Are we there yet?
Marta Magaz, Anna Baiges, Virginia Hernández‐Gea
Journal of Hepatology (2020) Vol. 72, Iss. 4, pp. 774-784
Closed Access | Times Cited: 64
Cardiodynamic state is associated with systemic inflammation and fatal acute‐on‐chronic liver failure
Michael Praktiknjo, Sofia Monteiro, Josephine Grandt, et al.
Liver International (2020) Vol. 40, Iss. 6, pp. 1457-1466
Open Access | Times Cited: 54
Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death
Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 6, pp. 1362-1373.e6
Open Access | Times Cited: 44
Beta-blockers in the era of precision medicine in patients with cirrhosis
Agustı́n Albillos, Aleksander Krag
Journal of Hepatology (2022) Vol. 78, Iss. 4, pp. 866-872
Closed Access | Times Cited: 32
Non‐selective beta‐blockers in patients with ascites: The complex interplay among the liver, kidney and heart
Luís Téllez, Agustı́n Albillos
Liver International (2022) Vol. 42, Iss. 4, pp. 749-761
Closed Access | Times Cited: 30
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients
Giovanni Marasco, Elton Dajti, Federico Ravaioli, et al.
Hepatology International (2020) Vol. 14, Iss. 5, pp. 850-857
Closed Access | Times Cited: 48
The Role of Vascular Injury and Congestion in the Pathogenesis of Cirrhosis: the Congestive Escalator and the Parenchymal Extinction Sequence
Ian R. Wanless
Current Hepatology Reports (2020) Vol. 19, Iss. 1, pp. 40-53
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top